Clinically, tumor proportional score (TPS) and combined positive score (CPS) based on immunohistochemical analysis of PD-L1 levels are the most widely used predictors of response to PD-1/PD-L1 blockade. This evidence concerns the gene PDCD1 and neoplasm.